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2.     List of abbreviations 
AA Arachidonic acid 
ACD Acid-citrate-dextrose 
ACEI Angiotensin converting enzyme inhibitor 
AMI Acute myocardial infarction 
ARB Angiotensin II receptor blocker 
ASA Acetylsalicylic acid 
AUC Area under the curve 
CABG Coronary artery bypass grafting 
CAD Coronary artery disease 
CCL CC chemokine ligand 
CD40 Cluster of differentiation 40 
CK-MB Creatine kinase MB isoenzyme 
COX Cyclooxygenase  
CRP C-reactive protein 
CXCL CXC chemokine ligand 
DAG Diacylglycerol 
DHA Docosahexaenoic acid 
ESI Electrospray-ionisation 
FA Fatty acid 
FDA Food and drug administration 
FDR False discovery rate 
g Gravity-force 
GC Gas chromatography 
GFR-MDRD Glomerular filtration rate (Modification of Diet in Renal 
Disease) 
GP Glycoprotein 
HDL High-density lipoprotein 
HDL-C High-density lipoprotein cholesterol 
HETE Hydroxyeicosatetraenoic acid 
HPLC High-performance liquid chromatography 
IR Infrared 
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LC Liquid chromatography 
LDL Low-density lipoprotein 
LOX Lipoxygenase 
Lp(a) Lipoprotein(a) 
LPA-R Lysophosphatidic receptor 
LVEF Left ventricular ejection fraction 
lysoPC Lysophosphatidylcholine 
lysoPE Lysophosphatidylethanolamine 
lysoPL Lysophospholipid 
MAPK Mitogen-activated protein kinase 
m/z Mass to charge ratio 
mo. Month 
MPO Myeloperoxidase 
MS Mass spectrometry 
NADP Nicotinamide adenine dinucleotide phosphate 
NMS Nanospray mass spectrometry 
no. Number 
non-HDL-C Non-high-density lipoprotein cholesterol 
NOS Nitric oxide synthase 
NOX NADPH oxidase 
OPLS-DA Orthogonal partial least squares discriminant analysis 
oxLDL Oxidized low-density lipoprotein 
PBS Phosphate buffered saline 
PC Phosphatidylcholin 
PCA Principal component analysis 
PCI  Percutaneous coronary intervention  
PCSK9 Proprotein convertase subtilisin/kexin type 9 
PDGF Platelet derived growth factor 
PE Phosphatidylethanolamine 
PECAM-1 Platelet endothelial cell adhesion molecule 1 
PG Prostaglandin 
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PI Phosphatidylinositide/phosphatidylinositol 
PKC Protein kinase C 
PL Phospholipid 
PLA2 Phospholipase A2 
PLS Partial least squares 
PPP Platelet poor plasma 
PRP Platelet rich plasma 
PS Phosphatidylserine 
psi Pound-force per square inch 
PUFA Polyunsaturated fatty acid 
QC Quality control 
QTOF Quadrupole time-of-flight 
RANTES Regulated on activation, normal T cell expressed and 
secreted 
ROS Reactive oxygen species 
rpm Revolutions per minute 
SAP Stable angina pectoris 
SM Sphingomyelin 
TG Triglyceride 
TGFb Transforming growth factor beta 1 
TLC Thin layer chromatography 
UHPLC Ultra-high performance liquid chromatography 
UV Ultraviolet 
V Volt 
VLDL Very low-density lipoprotein 
vWF  von Willebrand factor 
XO Xanthine oxidase 
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3.    Introduction 
3.1. Atherosclerosis 
 
Cardiovascular disease, especially atherosclerosis, is the leading cause of 
global death and premature disability in developed countries, accounting for 
more than 17.3 million deaths per year. The number is estimated to reach more 
than 23.6 million by 2030 (1). Atherosclerosis is a systemic disease induced by 
the accumulation of inflammatory cells in the intima layers of arteries (2). The 
pathogenesis of atherosclerosis is based on the building of atheromatous 
plaques in arteries, called atherogenesis. Depending on the damaged arteries 
atherosclerosis may manifest as a coronary artery disease, transient cerebral 
ischemia, renal artery stenosis, mesenteric ischemia or peripheral artery 
disease (3).  
3.1.1. Contribution of platelets to atheroprogression 
 
It has been proven that platelets not only take part in thromboembolic 
complications in advanced stages of atherosclerosis but also initiate the 
formation of atherosclerotic plaque and contribute to the development of the 
disease. There are two main mechanisms by which platelets contribute to the 
development of atherosclerotic lesions. Firstly, activated platelets adhere to the 
activated or inflamed endothelium based on a receptor/ligand interaction 
involving GP Ib/IX/V complex, vWF. Platelets can also interact with exposed 
subendothelial matrix components like collagen which leads to their activation 
(4,5). Platelets can also adhere to intact and/or inflamed endothelial monolayers 
and initiate endothelium activation. In vivo studies showed that platelet 
adherence to the endothelium of carotid arteries in apoE-deficient mice is 
initiated even without endothelial denudation or manifestation of atherosclerotic 
lesions (6). This interaction occurs in three steps: platelet tethering; platelet 
rolling ensured by selectin/endothelium communication, e. g. P-, E-selectins 
(4,7); and firm platelet adhesion ensured by integrins, e. g. GPIb, GPIIb-IIIa 
(these receptors contribute significantly to cell-cell interaction and platelet 
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aggregation) (5,8). These interactions result in receptor-specific activation 
signals in both platelets and endothelial cells.  
P-selectin contributes not only to platelet-endothelium communication, but its 
soluble form in plasma, generated by activated platelets and endothelial cells 
leads to a pro-coagulant state and contributes to the progression of 
atheromatous lesions (9). 
The second major mechanism attributing to atherogenesis is the production of 
pro-inflammatory chemokines by activated platelets (e. g. CCL3, RANTES 
(CCL5), CCL 7, CCL17, CXCL1, CXCL5, CXCL8 or CXCL12 as well as a 
precursor for CXCL7, such as β-thromboglobulin) and the inflamed 
endothelium. Their secretion is induced either by thrombin or by oxidized low-
density lipoproteins (oxLDL) which activate platelets. Chemokines induce pro-
inflammatory changes in endothelial and other inflammatory immune cells like 
monocytes, macrophages, lymphocytes; also promote the adhesion of platelet 
aggregates to the arterial wall. This, in turn, stimulates atherogenic monocyte 
recruitment and their subsequent differentiation into macrophages and foam 
cells (10,11). 
3.1.2. Development of atheromatous plaque 
 
Atherosclerotic plaques are defined as lipid-containing lesions on the intima of 
the wall of an artery. Hypercholesterolemia causes lipoprotein accumulation and 
binding to the extracellular matrix in the intima of the arteries which results in 
“fatty streaks” seen macroscopically (3). Plasma lipids, in particular native low-
density lipoproteins (LDL), are taken up by endothelial cells via LDL receptor-
mediated endocytosis (12). This facilitates oxidative modifications of 
lipoproteins whereby hydroperoxides, lysophospholipids, oxysterols, and 
aldehydic breakdown products of fatty acids and phospholipids are produced 
(3). OxLDL exhibit some new features compared to native LDL which enhances 
the proatherogenic process. Production of oxLDL and the chemoattractants, 
e.g. macrophage chemoattractant protein-1 produced by endothelial cells leads 
to an inflammatory response and triggers monocyte recruitment to 
subendothelial space (13). Certain cytokines (e. g. IL-1b, IFN- γ, tumor necrosis 
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factor a (TNF-a) induce the expression of leukocyte adhesion molecules on 
endothelial cells (13). These three pathways lead to monocyte accumulation in 
the arterial wall and their differentiation into macrophages.  
Once inhabiting the arterial intima monocyte-derived macrophages become 
able to express scavenger receptors for modified lipoproteins which lead to 
receptor-mediated endocytosis of modified lipoproteins and development of 
foam cells (14). Thus the “fatty streak”, a precursor of atherosclerotic plaque, is 
formed. 
The arterial lesion advances further as the smooth muscle cells proliferate and 
migrate into the intima the former being induced by transforming growth factor 
beta 1 (TGFb) which changes the contractile phenotype of the smooth muscle 
cells to a proliferative one (15). TGFb also markedly stimulates the smooth 
muscle cells to produce collagen 1 (16). The buildup of fibrous tissue leads to 
advancement and complication of atheromatous plaque. These processes are 
induced by various growth factors, e.g. platelet-derived growth factor (PDGF) or 
fibroblast growth factor, the production of which is driven by IL-1b or TNF-a 
(17). 
After the advanced plaque erodes and ruptures, platelets are activated and 
aggregate on the atherosclerotic plaque surface (18). Thrombotic occlusion of 
the artery leads to the manifestation of atherosclerosis with thrombo-ischemic 
events. 
3.1.3. Platelet and lipoprotein interplay 
 
Dysregulation in plasma lipoproteins is one of the most firmly established risk 
factors for atherosclerosis, most important ones being elevated LDL, very low-
density lipoprotein (VLDL) and triglyceride (TG) levels or decreased high-
density lipoprotein (HDL) levels as detected conventionally in plasma. In 
patients with hypercholesterolemia, platelets exhibit an increased activity and 
are hypersensitive to agonists, change their membrane phospholipid and cell 
lipid composition, as a consequence of platelet-lipid interaction (19).  
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Previously it has been shown that presence of oxLDL in the surrounding 
microenvironment of platelets enhances their aggregation. This response is 
substantiated by NADPH oxidase (NOX2)-derived reactive oxygen species 
(ROS) through a scavenger receptor CD36/protein kinase C (PKC) mediated 
pathway. Generation of ROS promote platelet hyperactivity in the means of 
modulating cGMP signaling (20). Activated platelet derived ROS potentiates 
oxidation of LDL to more atherogenic oxLDL in the external microenvironment 
(19). Recently it has also been shown that both LDL and oxLDL can trigger 
generation of mitochondrial superoxide and ROS generation in platelets which 
further propagates intraplatelet oxidative and peroxidative modifications to 
lipids, besides prompting their functional responses (21). 
Altered platelet functions are associated with LDL, VLDL, and especially oxLDL, 
which all contain apoprotein B-100 and are atherogenic lipoproteins. LDL 
stimulate platelets through a single receptor for lipoproteins called ApoE-R2’ 
(22–24). After binding LDL through ApoE-R2’ several intracellular cascades in 
platelets are initiated (Figure 1): 
- p38MAPK (mitogen-activated protein kinase) pathway activates 
phospholipase A2 (PLA2) which leads to enhanced production of 
prostaglandin endoperoxides by cyclooxygenase 1 (COX1) and 
thromboxane A2 by thromboxane synthase (Tx synthase). 
- PECAM-1 (platelet endothelial cell adhesion molecule 1) pathway inhibits 
the functions of the p38MAPK. 
- A third route leads to activation of focal adhesion kinase (FAK) which 
integrates different signaling pathways. 
- A fourth route leads to activation of a small GTPase Rap1b which 
stimulates activation of the integrin aIIbb3 on the platelet surface to 
support fibrinogen binding and platelet aggregation (24). 
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HDL is a heterogeneous lipoprotein and there exist two HDL subclasses (HDL2 
and HDL3). HDL2 fraction exhibits antiatherogenic effects by inhibiting platelet 
functions (thrombin-induced platelet aggregation, platelet shape change, Ca2+ 
mobilization, inositol phospholipids production, and reduction of NA-synthase 
expression induced by oxLDL) (25).  
As already mentioned above modified LDL uptake through scavenger receptors 
in macrophages leads to foam cell formation. Previous studies have shown that 
platelets also exhibit the ability to express scavenger receptors. 
Figure 1. Platelet activation by native LDL. Binding to ApoE-R2’ signals to p38MAPK, FAL and GTPase 
Rap 1b. Activation of cPLA2 leads to arachidonate release from membrane PL. Arachidonate is converted 
into endoperoxides by COX1 and the latter to TxA2 by Tx synthase. TxA2 acts synergistically with platelet 
agonists (ADP, thrombin, collagen). Integrin aIIbb3 is activated and binds soluble fibrinogen. Platelet 
aggregation is initiated. PECAM1 pathway inhibits the signaling through p38MAPK (modified from 24). 
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- Class B scavenger receptor CD36 which binds to oxLDL is found on 
resting and activated platelets (26). 
- Class E scavenger receptor lipoxygenase-1 (LOX-1) was detected only 
on activated platelets and also exhibits affinity to oxLDL (27). 
- Class B scavenger receptor B1 binds the anti-atherogenic HDL and is 
inversely associated with cholesteryl ester content of platelets (28). 
Scavenger receptors also serve in platelet recognition by macrophages which 
then phagocyte platelets and accumulate their lipids resulting in foam cell 
formation (29). 
OxLDL enhances the above mentioned four intraplatelet pathways even 
stronger than naive LDL as oxLDL can affect platelets not only through the 
usual ApoE-R2’ receptors but also through scavenger receptors – CD36 and 
lysophosphatidic receptors (LPA-R) (24). 
Platelets also contribute to the progression of atheromatous plaques by being 
able to oxidize LDL extracellularly by producing ROS in their immediate 
microenvironment (19). 
3.2. Lipids 
Lipids are small hydrophobic or amphipathic molecules which originate entirely 
or in part by carbanion-based condensation of thioesters (fatty acyls, 
glycerolipids, glycerophospholipids, sphingolipids, saccharolipids, and 
polyketides) and/or by carbonation-based condensation of isoprene units 
(prenol lipids and sterol lipids) (30). In 2005 the International Lipid Classification 
and Nomenclature Committee developed a comprehensive lipid classification 
which organized lipids into eight categories based on biochemical and chemical 
principles: fatty acyls, glycerolipids, glycerophospholipids, sphingolipids, 
saccharolipids, polyketides (generated by condensation of ketoacyl subunits); 
and sterol lipids and prenol lipids (generated by condensation of isoprene 
subunits) (Table 1) (31).  
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Table 1. Current lipid classification (modified from 31).  
Category Structures in database 
Fatty acyls 2678 
Glycerolipids 3009 
Glycerophospholipids 1970 
Sphingolipids 620 
Sterol lipids 1744 
Prenol lipids 610 
Saccharolipids 11 
Polyketides 32 
 
The total number of lipid molecular species is determined by intrinsic possible 
covalent moieties and molecular variants that result from enzymatic or non-
enzymatic oxidation, nitrosylation, and other environmental factors (32). 
Lipids are either produced endogenously or incorporated into cells from dietary 
sources (33). Lipids possess a variety of functions which include storing energy, 
acting as structural components of cell membranes, and serving as second 
messengers of signal transduction (34).  
3.2.1. Phospholipids and glycerophospholipids in platelets 
 
The main structural lipids in platelets as in all mammalian cells are 
phospholipids. They consist of hydrophobic fatty acid oriented to the core of 
membrane and a polar headgroup facing the aqueous phase. Phospholipids 
serve as substrates for certain active species, including 1,2-diacylglycerol 
(DAG), fatty acids (FA), eicosanoids/prostaglandins (PG), 
phosphatidylinositides (PI), lysophospholipids (lysoPL), and lysophosphatidic 
acid. Indirect oxidation of PLs by LOX and cyclooxygenases (COX) leads to the 
formation of PL-esterified eicosanoids and PG. Lipid rafts containing certain 
amounts of sphingomyelins and free cholesterol are located in platelet plasma 
membranes. Platelets also contain neutral lipids, including 1,2-diacylglycerol, 
triglycerides and cholesterol esters (33). 
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The most abundant phospholipids in platelets are phosphatidylcholine (PC) 
(40%) and phosphatidylethanolamine (PE) (28%). Sphingomyelin (SM) and 
phosphatidylserine (PS) are less abundant (18% and 10% of total 
phospholipids). PE and PS face the cytosol and are used for intracellular 
signaling whereas PC and SM are distributed on the outer layer of the cell 
membrane. PS is externalized during platelet stimulation leading to 
procoagulant activity (33). Normally this PL asymmetry is ensured by ATP-
dependent enzyme flippase which keeps the PS internally in the plasma 
membrane of the platelet. An opposing enzyme scramblase initiates a 
substantial bidirectional trans-bilayer movement of PE as well as PS in 
thrombin-stimulated or apoptotic platelets (35,36). The externalized PS creates 
a negatively-charged pro-coagulant surface which enables calcium ions to form 
bridges with certain domains of coagulation factors. Factor Xa-Va complex 
enhances the activation of the prothrombinase complex and thrombin 
production from prothrombin is initiated (37). 
Impaired calcium-dependent surface exposure of PS on platelets and other 
cells as well as or deficiency of scramblase result in Scott syndrome, a 
congenital bleeding disorder. According to the latest research, a defective 
transmembrane protein anoctamin-6 also known as a calcium-dependent ion 
channel for chloride ions and cations was reported to be resulting in the 
phenotype of Scott syndrome platelets (38). 
3.2.2. Oxidized phospholipids 
 
Phospholipid-bound polyunsaturated fatty acids (PUFA) are the main target for 
non-enzymatic or enzymatic oxidation during which several biologically active 
products, such as unesterified oxidized fatty acids (e.g., hydroperoxides and 
isoprostanes) and lysoPL are generated. Non-enzymatic oxidation of PL-
esterified PUFA is induced by nonradical ROS (singlet oxygen), or by free 
radicals. The latter originate from non-enzymatic oxidation in the environment 
(e.g. air-pollution, radiation), or from endogenous oxidation, mediated by 
various enzymes, such as NOX, myeloperoxidase (MPO), nitric oxide synthase 
(NOS), xanthine oxidase (XO), or respiratory chain in mitochondria. The 
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produced peroxyl radical intermediates are further converted into different 
products through various subsequent reactions, e.g. oxidation, cyclization, 
fragmentation, oxygen atom transfer. (39) 
Enzymatic oxidation of PL-PUFA is only available by 12/15 lipoxygenases which 
insert dioxygen directly producing hydroperoxides (39). To date, three main 
families of oxidized PL have been described, two from 12-LOX (10 total lipids) 
and four families of sixteen esterified PG generated via COX-1 (total 26 lipids).  
 
Phospholipid oxidation was thought to be an accidental consequence of tissue 
damaging inflammation although it was recently proved to be a regulated 
receptor/agonist dependent process during activation of platelets (e. g. with 
thrombin, collagen or Ca2+ ionophore) (40).  
Arachidonic acid (AA) is one of the sources for a family of six 12-
hydroxyeicosatetraenoic acid (12-HETE) containing PL, comprising four PE and 
two PC (40). In vitro, HETE-PL, found in physiological amounts in liposomes, 
significantly enhance tissue factor-dependent thrombin generation in plasma 
and therefore exhibit a pro-coagulant function (40).  
Oxidation of DHA (docosahexaenoic acid)-containing PL in thrombin-activated 
platelets by 12-LOX results in production of four PE (18:0p/14-HDOHE-PE, 
18:0a/14-HDOHE-PE, 16:0a/14-HDOHE-PE and 16:0p/14-HDOHE-PE) and 
HOO 
Enzymatic oxidation 
LOX 12/15 
ROS initiated 
oxidation 
ROS producing 
enzymes (MPO, XO, 
NOS, NOX etc.) 
Non-enzymatic sources of 
ROS (air pollution, UV 
radiation, smoking) 
•OO 
Peroxyl radical 
Hydroxiperoxide 
Figure 2. Phospholipid oxidation via enzymatic or non-enzymatic oxidation, producing various oxidized 
lipid species (modified from 39). 
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one unidentified species at mass to charge ratio (m/z) 818.6. These PE were 
only observed in activated platelets and supposedly exhibit antiplatelet activity 
by antagonizing the HETE-PL actions although the hypothesis is still being 
tested (41). 
Free radical-induced oxidation of 1-palmityl-2-arachidonyl-sn-glycero-3-
phosphocholine (PAPC) generates various polyunsaturated phospholipid 
peroxyl radicals which are transformed into oxidized phospholipids after 
undergoing cyclisation and fragmentation reactions. These oxPLs promote 
adhesion of monocytes to endothelium which is a similar property to that of low-
density lipoproteins minimally modified by mild oxidation (MM-LDL) (42).  
 
Figure 3. Overview of products of lipid oxidative fragmentation. Oxidative cleavage of PAPC generates 
POVPC. Similarly oxidation of PLPC generates PONPC (42). 
 
1-palmityl-2-(5-oxovaleryl)-sn-glycero-3-phosphocholine (POVPC) increases 
monocyte binding to endothelial cells whereas 1-palmityl-2-(5-glutaryl)-sn-
glycero-3-phosphocholine (PGPC) induces both monocyte and neutrophil 
binding by promoted E-selectin and vascular cell adhesion molecule (VCAM) 1 
expression. POVPC can be converted into PGPC under prolonged oxidative 
conditions whereas the biological activities of PGPC overtake those of POVPC 
(42). Moreover, PGPC promotes monocyte maturation and uptake of oxLDL 
whereby foam cells are formed. Both POVPC and PGPC induce apoptosis by 
increased expression of caspase. Increased apoptosis of macrophages as well 
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as the proliferation of smooth muscle cells (induced by POVPC) lead to 
progression of atherosclerosis.  
3.2.3. Sphingophospholipids (SP) and ceramides 
 
SPs together with glycerophospholipids and sterols are one of the most 
important cell membrane lipids. Sphingolipids consist of a sphingoid long chain 
base (normally sphingosine, sphinganine or phytosphingosine) and FA attached 
to it. The simplest of SP is ceramide which takes part in cell signaling and acts 
as a precursor of more complex SP (43). SP act as constituents of cell 
membranes which protect them against harmful environmental factors. SP also 
function as intracellular signaling messengers (33,43).  
Most abundant ceramides in human plasma are C24:0 and C24:1 and their 
concentration was showed to positively correlate with concentrations of total 
cholesterol (TC) and TG. Therefore ceramides might be potential risk factors at 
early stages of atherosclerosis (44). Certain ceramides were significantly 
associated with mortality from CVD and could improve the predictive potential of 
GRACE and Marschner scores. Furthermore, research suggests that ceramides 
of different chain-length have a different effect on atherosclerosis development. 
E.g. long-chain species (d18:1/16:0 and d18:1/18:0) were observed to be more 
harmful than very-long-chain (d18:1/24:0) species (45). 
Sphingosine-1-phosphate is generated after sphingosine is phosphorylated by 
sphingosine kinases and released from the granules during platelet activation 
(33). S1P regulates cell proliferation and migration, immune regulation, vascular 
development, brain inflammation and has shown to exhibit a role in 
thrombopoiesis (33,46). Activated platelets release huge amounts of S1P during 
blood clotting (47). It was also shown that intracellular and extracellular pools of 
S1P exist. The extracellular S1P is a platelet activator which induces platelet 
shape changes and platelet aggregation (48).  
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3.2.4. Lysophospholipids (lysoPL) and lysophosphatidic acid (LPA) 
LysoPL and LPA are generated from membrane phospholipids and 
sphingolipids (SL) by phospholipases, e.g. PLA2. They act as extracellular 
mediators by activating G-protein coupled receptors (GPCR) and regulate 
diverse cellular responses (49). Lysophosphatydilcholine (lysoPC) activates 
endothelial cells and recruits phagocytic cells during apoptosis (50). It is also a 
major component of oxLDL and contributes to its atherogenic effects (51). 
Activated platelets produce various lysoPL because of actions of PLA2 (52). 
The oxidation products of PLA2 become substrates for a higher demand of 
energy in activated platelets which links the lipid oxidation with energetic 
processes in mitochondria. Fatty acids and various eicosanoids, generated via 
PLA2, are acutely used as a source for mitochondrial beta-oxidation generating 
energy supplies needed for keeping the asymmetry of the plasma membrane, 
assuring the production of oxidized PL in activated platelets etc. (53). 
3.3. Lipidomics 
Lipidomics is one of the branches of metabolomics, analyzing different lipid 
species and their multiple functions in the living system (54). 
In general analysis of lipids consists of three main steps: 
- Preparation and extraction of lipids from biological materials e.g. 
serum/plasma, cellular extracts; 
- Lipid fragmentation by the means of enzymatic or non-enzymatic 
reactions and subsequent analysis of the fragmentation products; 
- Analysis of prepared, non-fragmented lipids by means of elementary 
analysis, UV- and IR-spectroscopy, mass spectrometry (MS) or NMS-
spectrometry (34). 
Traditional techniques for studying lipids include thin layer chromatography 
(TLC), gas chromatography/mass spectrometry (GC/MS), and high-
performance liquid chromatography (HPLC) coupled to radioactive, ultraviolet or 
fluorescence detection (33). 
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The major disadvantages of older approaches over liquid chromatography-mass 
spectrometry (LC/MS) are (i) low sensitivity and selectivity (TLC, HPLC), (ii) 
time-consuming derivatization methods (e.g. for GC/MS), and (iii) health issues 
associated with the usage of radioisotopes (33). These disadvantages 
subsequently led to the development of more sophisticated techniques with 
higher sensitivity and specificity, leading to better qualitative and quantitative 
accuracy of results.  
Lipidomics investigations use the two major methods, which include a highly 
sensitive and quantitative liquid chromatography-tandem mass spectrometry 
(LC/MS/MS), and “shotgun” lipidomics approach, based on direct infusion of 
complex mixtures into a spectrometer without former separation, which detects 
only the most abundant species (32). 
A newer quantitative approach is a combination of LC with a high-resolution 
MS/MS on rapid scanning Fourier transform (FT) or Time-of-flight (ToF) 
instruments, termed multidimensional MS (MDMS). In Fourier transform mass 
spectrometry, mass is measured by detecting the image current generated by 
ions in a magnetic field. ToF machines calculate mass based on the time (m/z 
ratio) it takes for molecules in an electric field to reach a detector at a certain 
distance. It takes longer for heavier molecules to reach the detector (55). 
Lipidomics approach is fundamental for understanding of lipid biology. It can 
also be applied in the clinical setting. Certain novel lipids can help detect 
cardiovascular diseases in early stages by the means of potential lipids being 
used as biomarkers with high-risk assessment values of prognostic impact. 
Moreover, it can aid in deciphering new targets for therapeutic interventions 
(53).  
3.4. Lipids in human blood stream 
Cholesterol is the main sterol of all higher animals, found in body tissues, 
especially the brain and spinal cord, and is a major constituent of animal fats 
and oils. Cholesterol is transported in the blood as particles containing both lipid 
and proteins – lipoproteins. Three major classes of lipoproteins are found in the 
plasma of a fasting individual: LDL, VLDL and HDL cholesterols. LDL is the 
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major carrier for cholesterol. It contains a single apolipoprotein, namely apoB-
100 (24,56). LDL cholesterol is the main atherogenic cholesterol and is directly 
associated with cardiovascular disease (57,58). Therefore LDL cholesterol is 
the primary target of cholesterol-lowering therapies as well as a marker for the 
efficacy of the initiated treatment. In contrast, HDL exhibits an anti-atherogenic 
effect.     
In order to estimate cardiovascular risk using various scores (e. g. Framingham 
risk calculator, ESC SCORE, PROCAM) baseline lipid profile of TC, TGs, HDL 
and LDL cholesterols is determined in fasting plasma. In patients with 
hypertriglyceridemia values of lipids may be inaccurate leading to 
underestimation of actual lipid status (59). That is why additional plasma lipid 
markers may be considered, e. g. lipoprotein A, apoB:apoA1 ratio or nonHDL-
C:HDL-C ratio.  
Potential markers may be distinct ceramide species which showed to predict 
cardiovascular death significantly better, compared to the currently used lipid 
markers (45). Moreover, some ceramide species not only were significantly 
associated with mortality in CAD but also were superior in predicting mortality in 
CAD to currently used standard LDL-C measurement (60). Further studies 
identified lysoPC and SM associated with CAD. LPC16∶0 or LPC20∶4 were 
associated with a decreased risk of developing CVD over the 12-year follow-up 
period whereas SM38∶2 was associated with increased odds of future CVD 
(61). 
Another factor promoting research of novel non-invasive atherosclerosis 
biomarkers is disease detection at its earliest. Establishing new atherosclerosis 
markers may as well lead to the development of novel treatment options. 
Recent studies identified six classes of ceramide synthases which might 
potentially be novel therapeutic targets in the diseases in which the ceramide 
acyl chain length is altered (62). The novel PCSK-9 inhibitors which are already 
applied in clinical practice were shown to decrease the plasma levels not only of 
LDL-C but also of CVD associated ceramides (60).  
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3.5. Lipid biomarkers in the context of CAD 
TC and LDL-C are proven independent CVD risk factors and have been 
established as lipid biomarkers for estimating the risk of CVD as well as 
following the clinical course of the disease (63). At last but not the least they are 
the main therapeutic targets of the current lipid-lowering therapy.  
HDL-C is an anti-atherogenic LPL as it is able to remove cholesterol from cells, 
inhibit LDL-C oxidation and exhibits anti-inflammatory features (64). Low HDL-C 
level is independently associated with higher CVD risk (65).  
Hypertriglyceridemia is also an independent CVD risk biomarker although its 
association with CVD is weaker than that of LDL-C (66). 
Total amounts of cholesterol in LDL, intermediate-density lipoprotein, remnant, 
and VLDL, comprise another calculated parameter called a non-high-density 
lipoprotein cholesterol (non-HDL-C). This combination of all the pro-atherogenic 
lipids can estimate CVD risk even more accurately than LDL-C (67).   
Several other biomarkers are gaining its way into clinical practice. Apoprotein B 
(apoB) is the main apoprotein of atherogenic lipoproteins. Higher plasma levels 
of apoB are also associated with a higher CVD risk (65). Lipoprotein(a) [Lp(a)] 
constitutes of an LDL attached to an additional protein called apolipoprotein(a). 
High levels of Lp(a) are associated with increased risk of CVD (65).  
3.6. Current lipid-lowering therapies   
Statins are inhibitors of 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase 
(HMG-CoA reductase), a rate-limiting enzyme in cholesterol synthesis. 
Decreased hepatic cholesterol concentrations lead to up-regulated synthesis of 
LDL receptors so that the clearance of LDL-C from the blood into hepatic cells 
increases and the pro-atherogenic LDL-C levels in the blood are reduced. (56) 
Lowering LDL-C levels in patients with ACS showed significantly lower mortality 
rates in the PROVE-IT clinical trial (68). Nevertheless, statins exhibit a variety of 
pleiotropic functions such as anti-inflammatory effects, mediated by both direct 
(modulation of the immune-response) and indirect (inhibition of platelet 
functions) mechanisms (69).  
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Another LDL-C lowering agent is ezetimibe – one of the agent of azetidinone 
cholesterol absorption inhibitors (56). Ezetimibe used in combination with a 
statin showed to significantly lower LDL-C levels and improve cardiovascular 
outcomes in ACS patients (70). 
Fibrates are fibric acid derivatives which reduce VLDL secretion from 
hepatocytes. Fibrates reduce levels of circulating VLDL, therefore lowering TAG 
levels with a modest (approximately 10%) reduction in LDL-C (56).  
Cholestyramine is one of the bile acid sequestrants which also lowers the levels 
of LDL-C. Binding the bile acids enhances their synthesis in liver from 
cholesterol which causes clearance and reduction of the levels of LDL-C from 
the circulation (71). 
Nicotinic acid raises HDL-C and reduces LDL-C levels. Nicotinic acid also 
uniquely lowers Lp(a) levels (72). 
The most novel lipid-lowering agents are monoclonal antibodies inhibiting the 
proprotein convertase subtilisin/kexin type 9 (PCSK9), which is involved in the 
degradation of LDL receptors in the liver. Inhibition of PCSK9 results in 
increased numbers of LDL receptors and enhanced hepatic LDL clearance (73).  
One of the PCSK9 inhibitors, evolocumab, was showed to significantly reduce 
LDL-C levels and the risk for cardiovascular events, in combination with 
standard therapy (statin), as compared with standard therapy (statin) alone. 
Levels of the Lp(a) could also be significantly reduced (74).  
Moreover, loss-of-function mutations in PCSK9 resulted in reduced plasma 
LDL-C levels.  Inhibiting the PCSK9 synthesis by a small interfering RNA (ALN-
PCS) showed a mean 40% reduction of LDL-C compared to placebo (75). 
Clinical application of the new approach by means of RNA interference needs to 
be further investigated. 
3.7. Current guidelines on lipid-lowering therapies 
The guidelines on cardiovascular disease prevention used in the clinical 
practice focus mainly on a statin-based primary or secondary prevention. The 
most recent guidelines from 2016 published by the European Society of 
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Cardiology (ESC) or the guideline from 2013 from the American Heart 
Association (AHA) both recommend estimating the 10-year risk of a first fatal 
atherosclerotic event, either using the European SCORE (Systemic Coronary 
Risk Estimation) system or the American 10-year ASCVD (atherosclerotic 
cardiovascular disease) risk calculator. After determining the estimated 10-year 
risk patients are categorized in different groups (low, moderate, high, very high) 
depending on the estimated CVD risk, based upon which different dosages of 
statins are prescribed. The European guidelines focus on reaching a certain 
LDL-C level under the statin-therapy. On the contrary, the American guideline 
does not suggest an absolute target level of LDL-C and recommends initiating a 
certain intensity statin-treatment to reduce the LDL-C levels by ≥50 % or 30–50 
% in high or moderate risk patients (65,76). Ezetimibe is recommended as a 
supplement to the statin-therapy when the levels of LDL-C cannot be reduced 
under the highest-dose statin monotherapy. Fibrates are also combined with 
statins, especially in cases of severe hypertriglyceridemia (65). PCSK9 
inhibitors are still gaining their way into guidelines on CVD prevention as the 
impact of PCSK9 inhibitors on cardiovascular outcomes is still being 
investigated and the first results have been recently published. Additional 
indications for a therapy with PCSK9 inhibitors include familial 
hypercholesterolemias whereas only in combination with other lipid-lowering 
agents.  
3.8. Aims of the study 
After reviewing the literature on the lipid biology, platelet and lipid interactions 
as well as the pathogenesis of atherosclerosis the following aims of this study 
where formulated: 
1. Demonstrate the effect of oxLDL on platelet aggregation 
2. Examine the platelet lipidome in healthy subjects compared to STEMI 
and SAP patients 
3. Extract the most significantly abundant lipid species in platelets of SAP 
and STEMI patients 
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4.    Materials and methods 
 
4.1. Materials 
4.1.1. Chemicals 
Chemical Source 
1-heptadecenoyl-2-
eicosatetraenoyl-sn-glycero-3-
phosphocholine (PC (17:0/20:4)) 
Avanti Polar Lipids, Inc. (Alabaster, AL, 
USA) 
1-heptadecenoyl-sn-glycero-3-
phosphocholine (LysoPC 17:1) 
Avanti Polar Lipids, Inc. (Alabaster, AL, 
USA) 
1-Palmitoyl-2-(5-oxovaleroyl)-sn-
glycero-3-phosphocholine (POVPC) 
Avanti Polar Lipids, Inc. (Alabaster, AL, 
USA) 
1-palmitoyl-2-(9-oxononanoyl)-sn-
glycero-3-phosphocholine (PONPC) 
Avanti Polar Lipids, Inc. (Alabaster, AL, 
USA) 
1-palmitoyl-2-azelaoyl-sn-glycero-3-
phosphocholine (PAzPC) 
Avanti Polar Lipids, Inc. (Alabaster, AL, 
USA) 
1-palmitoyl-2-glutaryl-sn-glycero-3-
phosphocholine (PGPC) 
Avanti Polar Lipids, Inc. (Alabaster, AL, 
USA) 
Acetonitrile  Sigma-Aldrich Chemie GmbH, 
München, Germany 
Ammonium acetate Sigma-Aldrich Chemie GmbH, 
München, Germany 
Citric acid Sigma-Aldrich Chemie GmbH, 
München, Germany 
D-(+)-Glucose Sigma-Aldrich Chemie GmbH, 
München, Germany 
Ethanol, 75% Carl Roth, Karlsruhe, Germany 
Hydrochloride acid  Carl Roth, Karlsruhe, Germany 
Isopropanol Carl Roth, Karlsruhe, Germany 
Magnesium chloride hexahydrate Merck KGaA, Darmstadt, Germany 
Potassium chloride Carl Roth, Karlsruhe, Germany 
Potassium dihydrogen phosphate Merck KGaA, Darmstadt, Germany 
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Sodium chloride BioChemica AppliChem GmbH, Darmstadt, 
Germany 
Sodium hydrogen carbonate Merck KGaA, Darmstadt, Germany 
tri-Sodium citrate dihydrate Merck KGaA, Darmstadt, Germany 
Trizma® base Sigma-Aldrich Chemie GmbH, 
München, Germany 
 
4.1.2. Solutions/buffers 
Solution Components 
6 mM hydrochloride acid  
ACD buffer 7 mM citric acid 
22 mM tri-Sodium citrate dihydrate 
25 mM glucose 
6 mM hydrochloride acid 
JNL buffer JNL A 5 ml 
JNL B 5 ml 
JNL D 5 ml 
JNL E 0,5 ml 
ACD pH 7,2 
Distilled water 
JNL A  60 mM glucose 
Distilled water 
JNL B 1,3 M sodium chloride 
90 mM sodium hydrogen carbonate 
100 mM tri-Sodium citrate dihydrate 
100 mM Trizma® base 
30 mM potassium chloride 
Distilled water 
JNL D 8,1 mM potassium dihydrogen 
phosphate 
Distilled water 
JNL E 90 mM magnesium chloride 
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hexahydrate 
 
4.1.3. Laboratory materials 
Material Source 
10 ml pipette Corning Incorporated, NY, USA 
15 ml Falcon tube Greiner Bio One, Frickenhausen, 
Germany 
20 ml syringe B. Braun, Melsungen, Germany 
50 ml Falcon tube Greiner Bio One, Frickenhausen, 
Germany 
Eppendorf Safe-Lock Tubes 1.5 ml Eppendorf AG, Hamburg, Germany 
Pasteur pipette RatioLab GmbH, Dreieich, Germany 
 
4.1.4. Devices 
Product name Source 
Agilent 1290 UHPLC instrument Agilent Technologies, Waldbronn, 
Germany 
Eppendorf centrifuge 5417 Eppendorf AG, Hamburg, Germany 
Hettich® ROTANTA 460/460R 
centrifuge 
Andreas Hettich GmbH & Co.KG, 
Tuttlingen, Germany 
Multiplate® Analyzer Roche Deutschland Holding GmbH 
Phenomenex Kinetex C8 column Phenomenex, Inc., CA, USA 
PIPETBOY acu 2 INTEGRA Biosciences AG 
Sciex TripleTOF 5600+ hybrid mass 
spectrometer 
Agilent Technologies, Waldbronn, 
Germany 
Sysmex KX-21N™ Automated 
Hematology Analyzer 
Sysmex Deutschland GmbH, 
Nordertstedt, Germany 
Tisch-pH/Ionen-Messgerät 
SevenCompactTM S220, pH-Meter 
SevenCompactTM S220-basic 
Carl Roth GmbH + Co. KG, Karlsruhe, 
Germany 
Ultra-sonication bath BANDELIN electronic GmbH & Co. 
KG, Berlin, Germany 
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Vortex mixer IKA Labortechnik, Staufen, Germany 
 
4.2. Methods  
4.2.1. Study design 
 
HYPOTHESIS  
Role of platelets for lipid changes in CAD 
STUDY DESIGN 
Experimental prospective study in patients with 
and without CAD (270/2011 BO2) 
Literature review 
Lipidomics in clinical 
context of CAD 
STEMI SAP Healthy 
Sample collection and preparation 
Figure 4. Hypothesis and patient selection. 
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4.2.2. oxLDL effect on platelet aggregation 
In order to test the hypothesis that platelet aggregation is enhanced by oxidized 
lipids, which plays a crucial role in the development of atherosclerosis, effect of 
oxLDL on platelet aggregation was examined. Peripheral blood was collected 
from 7 healthy subjects in hirudin anticoagulant. 270 µl of whole blood was 
incubated with oxLDL (1 mg/ml). In another setting 30 µl of phosphate buffered 
saline (PBS) Ca2+ was added to 270 µl of blood as a control set. Blood samples 
were incubated in room temperature for 30 minutes and afterwards analyzed 
with Multiplate® analyzer. The aggregation was induced with ADP (6,5 µM). 
The aggregation curves were registered for 6 minutes. Platelet aggregation data 
were represented as area under the curve (AUC). 
 
 
 
Platelet isolation 
Lipid extraction 
UHPLC-ESI-QTOF-MS/MS 
Blood samples from healthy subjects and 
patients with SAP and STEMI 
Identification of significant lipids in 
SAP and STEMI 
Data interpretation 
Sample preparation 
and analysis 
Figure 5. Sample acquisition and workflow. 
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4.2.3. Study population 
 
Blood samples from patients presenting with a STEMI (n=13) were collected in 
less than two hours after onset of symptoms before the percutaneous coronary 
intervention (PCI). Patients with stable angina pectoris (SAP) (n=10) were also 
included in the study. 10 healthy subjects served as a control group to compare 
all the data with STEMI and SAP patients. Blood samples from SAP patients 
were collected before the PCI during the admission at the hospital. All patients 
were admitted to the Department of Cardiology at the University Clinic of 
Tübingen, Germany. The study was approved by the institutional ethics 
committee (270/2011BO2) and complies with the declaration of Helsinki and 
good clinical practice guidelines. All subjects gave written informed consent.  
STEMI was diagnosed by a rise and/or fall of cardiac troponin and symptoms of 
ischemia, and/or typical changes in electrocardiogram, and/or signs of new 
ischemia in cardiac imaging, and/or an intracoronary thrombus detected by 
coronary angiography (2). Stable coronary artery disease was characterized by 
transient chest pain (angina pectoris) episodes caused by reversible ischemia 
or hypoxia in myocardium, occurring under physical or emotional stress (74). 
Healthy volunteers presented with no obvious symptoms of disease and were 
free of medication at the time of donating blood (n=10, age (mean ± SD) 30 ± 7 
years). 
4.2.4. Platelet isolation 
 
40 ml of whole blood was collected into two 20 ml syringes each filled with 3 ml 
ACD anticoagulant and distributed into four 15 ml Falcon tubes afterward. The 
blood was centrifuged at 200 x g for 10 minutes with no brakes applied, at room 
temperature. The upper two thirds of platelet rich plasma (PRP) were 
transferred into a 50 ml Falcon tube containing Thyroid buffer (composition) pH 
6.4 using a Pasteur pipette. The PRP samples were centrifuged at 150 x g for 7 
minutes with brake level 2 under maximum speed at room temperature to 
separate platelets. The centrifuged platelet pellet was transferred into a 50 ml 
Falcon tube using a Pasteur pipette and resuspended in 500 μl of acidic 
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ethanol. Resting platelet suspension (1 ml) containing 300x103/μl platelets was 
transferred into a 1.5 ml Eppendorf tube, which was placed in an ultra-
sonication water bath with ice for cooling for 20 minutes. After the ultra-
sonication, the platelet suspension was placed on a vortex mixer for 10 s and 
then centrifuged at 2100 rpm for 5 minutes under 4°C. 500 μl of the platelet 
supernatant were transferred into an Eppendorf tube and stored at -20°C 
temperature. 
Measurements described further on (4.2.5. – 4.2.8.) were performed in 
cooperation with Prof. Dr. Michael Lämmerhofer and Jörg Schlotterbeck 
(Institute of Pharmaceutical Sciences, Universität Tübingen, Auf der 
Morgenstelle 8, 72076 Tübingen, Germany). Data analysis was done by Prof. 
Dr. Michael Lämmerhofer, Jörg Schlotterbeck and Dr. Madhumita Chatterjee 
(Department of Cardiology and Cardiovascular Sciences, Internal Medicine III, 
Universitätsklinikum Tübingen). 
4.2.5. Lipid extraction  
 
Supernatants after such extraction were dried under a gentle stream of nitrogen 
and reconstituted in 500µL of methanol. Samples were centrifuged, and the 
supernatant was carefully removed without disturbing the pellet. The entire 
sample preparation was carried out under light protection. The collected 
supernatants were spiked with internal standards (LPC(17:1), PC(17:0/20:4)) at 
a final concentration of 40 ng/mL and subjected to UHPLC-ESI-QTOF-MS/MS 
analysis (21). 
4.2.6. UHPLC-ESI-QTOF-MS/MS  
 
LC-MS/MS analysis of the lipid extract was carried out on an Agilent 1290 
UHPLC instrument hyphenated to a Sciex TripleTOF 5600+ hybrid mass 
spectrometer. A Phenomenex Kinetex C8 column (150 x 2.1 mm; 2.6 µm) was 
used for chromatography. Solvents were aqueous 10 mM ammonium acetate 
(A) and a mixture of acetonitrile, isopropanol and water (55:40:5 v/v) containing 
10 mM ammonium acetate (B). The gradient was 10% B to 40% B in 2 minutes 
and 100% B in 20 minutes followed by a cleaning step of 10 minutes 100% B 
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and 2 minutes equilibration with 10% B at a flow rate of 400µL/min and 50°C 
oven temperature. Injection volume was 2µL.  
The MS platform was operated in ESI positive mode at 5000V and 500°C. 
Nebulizer, heater and curtain gas were used at 50, 40, 30 psi respectively. 
Declustering potential was set to 100 V. Data-independent MS/MS acquisition 
was carried out using SWATH 2.0 covering a range of 30-1000 m/z with 
optimized Q1 windows using a quality control (QC) sample and swathTUNER. 
31 SWATH windows were used with a minimum size of 5Da in high sensitivity 
mode.  
The collision energy was 35V for each window. Data processing was done with 
commercial software PeakView, MasterView and MarkerView (Sciex) and freely 
available MS-DIAL5. 
Data quality was evaluated by a QC sample which was embedded throughout 
the analysis batch consisting of 44 injections in total with 11 injections of the QC 
sample (3 x before analysis of the first sample, 3 x after the last sample and the 
other injections of the QC sample distributed within the sample sequence after 
every 5th injection of a sample). It is a commonly accepted quality attribute for 
untargeted profiling methods in lipidomics and metabolomics if the QC samples 
injected across the entire sequence are closely grouped together and largely 
superimposed upon each other in the score plot of multivariate statistical 
procedures like PCA, PLS or OPLS-DA. In the present study, the detected 
molecular features (ca. 7,500 in the QC sample in the positive mode) were 
subjected to MS-DIAL for peak finding, LOWESS normalization and 
identification via spectral matching. Logarithmic transformation to the base e 
and autoscaling was done with MarkerView software. Subsequently, these 
responses were subjected to supervised principal component analysis-
discriminant analysis (PCA-DA). The results are illustrated in Figure 7 which 
clearly documents a clustering of the distinct sample classes (QC, healthy 
control R, STEMI and SAP) and most importantly the QC samples are totally 
superimposed upon each other meaning that the assay has been robust and 
thus the results have been highly consistent throughout the analysis batch. This 
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documents the stable performance of the LC-MS assay during the analysis 
sequence and high precision of retention times, mass accuracies, and 
responses throughout the assay. CV values of retention time and intensity of 
the internal standards were 0.4 % and 12 % for LPC(17:1) and 0.2 % and 10 % 
for PC(17:0/20:4) respectively. These data clearly document the reliability of the 
measurements (21). 
4.2.7. Data analysis  
 
From thousands of molecular features detected by UHPLC-ESI-QTOF-MS/MS, 
distinct marker lipids from healthy and CAD patients were extracted by t-tests 
and volcano plots after structural annotation by MS-DIAL and LipidBlast 
database search. Annotated lipids with P-value ≤0.05 in the comparison 
between CAD (STEMI or SAP) and the healthy group were used to construct a 
heat map (Figure 8) in order to visualize the differences in lipid abundances 
among the distinct groups. Of the 3054 molecular features extracted from 
ESI(+) mode data, 695 molecular features exhibited significantly different 
abundance in lipid extracts of healthy and STEMI platelets. 172 of them could 
be identified by manual revision of spectrometric data in MS-DIAL and 
LipidBlast database as shown in the heat map (Figure 8) indicating different 
lipid classes. Free radical–induced oxidative cleavage of 1-palmityl-2-
arachidonyl-sn-glycero-3-phosphocholine (PAPC) generates POVPC that is 
further oxidized to PGPC. POVPC is the aldehydic fragmentation product from 
PAPC, while PGPC is the carboxylic acid product following further oxidation. 
Oxidative cleavage of 1-palmityl-2-linoleyl-sn-glygero-3-phosphocholine (PLPC) 
generates PONPC that is further oxidized to PAzPC. For these oxidized lipids, 
standards were available, and their structures could, therefore, be manually 
annotated to their respective peaks in the chromatograms (21).  
4.2.8. Statistical analysis  
 
Samples for the lipidomics study comprised lipid extracts from healthy controls 
(n=10), SAP (n=10) and STEMI (n=13) patients. Raw data from the UHPLC-
ESI-QTOF-MS/MS analysis (Sciex wiff files) were imported into MS-DIAL and 
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pre-processed before statistical analysis (peak alignment, noise filtering, 
LOWESS normalization, structure annotation). In compliance with FDA 
guidelines on bioanalytical method validation, the intra-assay precision of raw 
signal intensities was < 15%, as estimated by internal standards as surrogate 
variables. Limits of detection are substance-dependent and typically in the low 
ng/ml-range. Preprocessed data (normalized peak areas) were exported from 
MS-DIAL and used for univariate and multivariate statistical analysis. 
Normalized peak areas were log-transformed and subjected to unpaired 
Student t-test to identify peaks varying significantly (p ≤0.05) between distinct 
groups. Only molecular features with p ≤0.05 (uncorrected) were then further 
processed and considered as putative biomarkers of potential interest. 
Responses for these lipids are presented as a heat map (Figure 8). To account 
for the problem of multiple hypotheses testing a false discovery rate (FDR) 
controlling procedure was further adopted to correct significance levels for FDR 
≤5% according to Benjamini and Hochberg. Multivariate statistical data analysis 
was performed using MarkerView (Sciex). Normalized peak areas were log-
transformed and autoscaled before they were subjected to principal component 
analysis–discriminant analysis (PCA-DA) (21).  
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5.    Results  
 
5.1. Baseline characteristics of the patient cohort 
Characteristics STEMI (n=13) SAP (n=10) 
Male 11 (84.6%) 8 (80%) 
Female 2 (15.4%) 2 (20%) 
Age (mean ± SD) 71.5 (± 11.8) 64.8 (±13.7) 
BMI (mean ± SD) 25.23 (±2.59) 29.23 (±4.1) 
CVRF 
Arterial Hypertension 11 (84.6%) 8 (80.0%) 
Hyperlipidemia 5 (38.5%) 3 (30.0%) 
Diabetes mellitus 3 (23.1%) 3 (30.0%) 
Smoking 2 (15.4%) 3 (30.0%) 
Ex/Smoking (>6 mo.) 1 (7.7%) 2 (20.0%) 
Atrial fibrillation 1 (7.7%) 1 (10.0%) 
Positive family history 2 (15.4%) 1 (10.0%) 
Obesity 1 (7.7%) 3 (30.0%) 
LV Function (%) (Mean ± SD) 48.08 (±10.71) 54.80 (±8.26) 
LVEF normal 3 (23.08%) 7 (70.0%) 
LVEF mild impairment 5 (38.46%) 2 (20.0%) 
LVEF moderate impairment 3 (23.08%) 0 (00.0%) 
LVEF severe impairment 2 (15.38%) 1 (10.0%) 
Chronic kidney disease 1 (7.7%) 2 (20.0%) 
Renal function (GFR) (Mean ± SD) 80.87 (±26.84) 77.51 (±17.95) 
Medication on admission 
Acetylsalicylic acid 2 (15.4%) 5 (50.0%)  
Clopidogrel 0 (00.0%) 2 (20.0%) 
Prasugrel 0 (00.0%) 1 (10.0%) 
Ticagrelor 0 (00.0%) 1 (10.0%) 
Oral anticoagulants 0 (00.0%) 2 (20.0%) 
Angiotensin-converting enzyme 1 (7.7%) 5 (50.0%)  
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inhibitors 
Angiotensin II receptor antagonists 2 (15.4%) 1 (10.0%) 
Aldosterone antagonists 0 (0.00%) 1 (10.0%) 
Diuretics 1 (7.7%) 5 (50.0%) 
Calcium channel antagonists 2 (15.4%) 3 (30.0%) 
Beta-blockers 3 (23.1%) 8 (80.0%) 
Statins 1 (7.7%) 6 (60.0%) 
Laboratory parameters 
Troponin I sensitive 19,96 (±25,10) not measured 
CK-MB 737,54 (±751,87) 119,30 (±83,29) 
Platelet count 261,69 (±61,60) 197,0 (±66,12) 
Cholesterol 169,00 (±37,02) 164,88 (±35,96) 
LDL-cholesterol 106,86 (±39,10) 101,0 (±32,61) 
HDL-cholesterol 39,29 (±21,20) 43,77 (±8,93) 
Triglycerides 123,10 (±70,70) 155,5 (±51,73) 
C-Reactive protein  2,40 (±3,12) 0,64 (±0,91) 
Leukocyte count 11260,0 (±3955,66) 7483,33 (±2049,3) 
Creatinine 0,96 (±0,31) 0,96 (±0,27) 
Hemoglobin 12,74 (±2,34) 13,69 (±1,96) 
INR 1,14 (±0,21) 1,23 (±0,59) 
PTT 67,46 (±50,36) 37,0 (±38,87) 
Bilirubin 0,73 (±0,39) 0,70 (±0,38) 
Glucose 160,0 (±110,8) 116,0 (±34,66)  
GOT 104,57 (±108,86) 26,88 (±6,71) 
GPT 32,38 (±18,73) 26,33 (±11,15) 
LDH 308,23 (±164,12) 203,22 (±37,91) 
 
5.2. oxLDL influenced platelet aggregation response to ADP 
In order to test the effect of oxidized lipids on platelet reactivity blood samples 
from 7 healthy subjects were examined. Platelet aggregation was induced with 
ADP in two settings – untreated whole blood vs. whole blood treated with 
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oxLDL. Measurements could show that oxLDL enhanced platelet aggregation 
(Figure 6). The average AUC in whole blood incubated with oxLDL was higher 
than in untreated whole blood samples. 
 
Figure 6. Platelet aggregation in whole blood (untreated vs. oxLDL), p=0,0156 (*, p<0,05).  
 
5.3. Lipid profile of circulating platelets  
To characterize the lipid profile of circulating platelets in STEMI and SAP 
groups blood samples were analyzed by lipidomics profiling using liquid 
chromatography hyphenated to high-resolution mass spectrometry (UHPLC-
ESI-QTOF-MS/MS) using data-independent acquisition with SWATH (77,78). 
The following measurements were performed by Prof. Michael Lämmerhofer 
and Jörg Schlotterbeck (Institute of Pharmaceutical Sciences, Universität 
Tübingen, Auf der Morgenstelle 8, 72076 Tübingen, Germany).  
The lipid profiles of 13 STEMI and 10 SAP patients were compared to 10 
healthy controls. 
The initial UHPLC-ESI-QTOF-MS/MS analysis detected over 7500 of molecular 
features in the samples of the healthy and CAD subjects (21). 
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The data was normalized and aligned as well as subsequently subjected to 
principal component analysis (PCA-DA). The score plot clearly illustrates how 
samples of the healthy controls (n=10), SAP (n=10) and STEMI (n=13) patients 
with similar lipid profiles are clustered closely together. The same plot also 
depicts how platelet lipid profiles differ in healthy subjects compared to CAD 
patients as well as among the SAP and STEMI patients (Figure 7) (21).  
Figure 7. Samples of healthy, SAP and STEMI patients clustering in different groups depending on 
lipid profile (21). In cooperation with Prof. Michael Lämmerhofer and Jörg Schlotterbeck.  
 
Out of more than 7500 primary molecular species distinct lipids were further 
extracted by t-tests and volcano plots which led to reduced number of molecular 
features which significantly differed in abundance among the three target 
groups (21). 
Out of 664 molecular features exhibiting significantly different abundance in lipid 
extracts of healthy and CAD platelets, 172 of them were identified by manual 
revision of spectrometric data in MS-DIAL and LipidBlast tandem mass 
spectrometry databases for lipid identification. Database search revealed 172 
known molecular structures with p-values ≤0.05 which were eventually 
classified according to the lipid class they belong to. The following heat map 
presents the significantly different expression of separate lipid classes among 
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STEMI, SAP and healthy subject groups (Figure 8) red color meaning the 
highest abundance and blue depicting the low abundant species (21). 
 
Figure 8. Heat map representing abundance of different lipid classes in healthy, SAP and ACS 
(STEMI) patients (21). TG – triglyceride, SM – sphingomyelin, PE – phosphatidylethanolamine, PC – 
phosphatidylcholine, MG – monoglyceride, DG – diglyceride, CER – ceramide, CE – cholesteryl 
ester. In cooperation with Prof. Michael Lämmerhofer and Jörg Schlotterbeck. 
 
Significantly higher levels of triglycerides (TG), phosphatidylcholin (PC), 
diacylglycerols (DG), monoacylglycerols (MG), plasmenyl-PCs (p-PC), 
sphingomyelin (SM) and ceramides (CE) were found in SAP patients as 
compared to healthy subjects (21). 
Abundance of distinct lipid metabolites – oxPLs, ceramides, cholesteryl-esters 
was further compared between healthy, SAP and STEMI subgroups. However, 
oxPLs are not contained in LipidBlast database and were therefore not 
annotated by MS-DIAL. For some specific oxidized lipids, standards were 
available, and their structures could therefore be manually annotated to their 
respective peaks in the chromatograms. Several oxPLs e.g. POVPC 
(m/z=594.3766), PGPC (m/z=610.3715), PONPC (m/z=650.4392) and PAzPC 
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(m/z=666.4341) were detected in the samples of the subgroups. They were 
elevated in SAP and were significantly increased in STEMI patients when 
compared to healthy subjects (Figure 9) (21). 
 
 
Figure 9. Expression of POVPC, PGPC, PONPC and PAzPC in the samples of the subgroups (21). In 
cooperation with Prof. Michael Lämmerhofer and Jörg Schlotterbeck.  
 
The same tendency was observed among other oxidized lipid metabolites. 
Several lysoPCs (18:1, 18:2, 22:6) were found to be elevated in SAP and 
STEMI patients compared to healthy controls (21). 
Cholesteryl esters (CE) (18:1, 18:2, 20:4, 20:5, and 22:6) levels were also 
significantly elevated in SAP and STEMI patients compared to healthy controls 
(21). 
Ceramide levels in platelets of SAP patients showed a different tendency in 
abundancy. Cer(d18:1/16:0), Cer(d18:1/18:0), Cer(d18:1/24:0) and 
Cer(d18:1/24:1) plasma levels were significantly downregulated in SAP 
compared to healthy controls. The levels of particular ceramides showed a 
significant downregulation between the subgroups. Cer 41:4;(d17:0/24:4) and 
Cer 42:5;(d18:1(4E)/24:4) were significantly downregulated in platelets from 
STEMI patients when compared to SAP (21). 
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6.    Discussion 
 
CVD is the major cause of worldwide mortality expected to reach the rate of 
23.6 million deaths per year by 2030 (1). The major cause accounting for 
cardiovascular mortality is CAD resulting in AMI and exerting its lethal 
complications. The reason for ischemic events of the large arteries is 
atherosclerosis, the pathophysiological mechanism of which lies in a systemic 
inflammatory state caused by circulatory platelet hyper-reactiveness and 
monocyte/macrophage and leucocyte accumulation in the intima of arteries. 
Hyperlipidemia is one of the factors contributing to systemic inflammation and 
the pathogenesis of atherosclerosis and is, therefore, one of the prominent 
cardiovascular risk factors. Another important factor is platelets and especially 
platelet-lipid interactions leading to enhanced thrombus formation on 
atherosclerotic lesions which exert in ischemic events (AMI, stroke etc.). 
Incubating whole blood from healthy subjects with oxLDL showed an enhanced 
platelet aggregation response (Figure 6). Therefore lipid oxidation products are 
also important contributors to the development of atherosclerosis. 
Lipids can contribute to platelet activation and ROS play a crucial role in this 
process along with other regulatory parameters which trigger the aggregation 
cascade (20). ROS production from phospholipids can be initiated not only by 
external triggers (e.g. UV radiation, smoking) but also be enzyme-induced 
during platelet aggregation. (39) Activation of platelets by different agonists also 
leads to the generation of a variety of intracellular lipid signaling intermediates 
and second messengers which contribute to platelet activation (21). Many lipid 
metabolites generated in the arachidonic acid pathway e.g. thromboxane, 
leukotrienes, oxPL can influence platelet activation acting as autocrine agonists 
or boost thromboinflammatory processes acting as paracrine inducers. Current 
experimental findings showing the synergistic effect of oxLDL on ADP induced 
platelet aggregation was one of the main reasons to further investigate other 
intraplatelet lipid metabolites which might influence platelet hyperreactivity in 
CAD patients and thereby contribute to atheroprogression. Moreover, a further 
aim was to compare the platelet lipid profiles between the healthy controls and 
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the subgroups of CAD, including the stable disease (SAP) and its advanced 
stage (STEMI).  
For the purpose of the study liquid chromatography hyphenated to high-
resolution mass spectrometry (UHPLC-ESI-QTOF-MS/MS) was applied. This is 
currently one of the leading lipid profiling method in lipidomics research 
providing highly sensitive and quantitative results. After global lipid profiling, 
specific lipid targets were investigated. 
The final cohort for lipidomics included 13 STEMI and 10 SAP patients which 
platelet lipid profiles were compared to 10 healthy controls. This study was one 
of the first ones to investigate lipid profile in the platelets in the clinical context. 
The study showed significant changes in platelet lipid profiles among healthy 
subjects and CAD patients (21). Platelets of SAP and STEMI patients showed 
higher abundance of various lipids and their metabolites compared to healthy 
subjects (21). As already discussed changes in the platelet lipid profile of CAD 
patients could arise from oxidative/peroxidative and differential enzymatic lipid 
metabolism which is reflective of the activation state of platelets and may 
constitute a driving mechanism of atherosclerosis. Atherogenic lipid metabolites 
enhance the inflammation in the intima layers of arteries and interact with 
platelets leading to their hyperreactivity both of which contribute to plaque 
building and their instability.  
Significant differences in platelet lipid profiles were also observed among the 
subgroups of CAD. Platelets of STEMI patients showed higher levels of most 
lipid metabolites compared to SAP patients (21). This confirms that AMI is the 
state of the most active platelet and lipid interaction where inflammatory and 
oxidation processes are the most active leading to the production and higher 
levels of oxidized lipid metabolites.  
Overall, the study identified 172 lipid species which were significantly more 
abundant in platelets of CAD patients compared to platelets of healthy 
individuals. Lipid species belonging to the main lipid classes including 
triglycerides (TG), phospholipids (PC), diacylglycerols (DG), monoacylglycerols 
(MG), plasmenyl-PC (p-PC), and sphingomyelin (SM) were detected. (21) 
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Ceramides were recently confirmed to be significant predictors of CVD, 
independent of currently used lipid markers (45). 
Another important aspect of the study was the platelet oxPL profile in CAD 
patients (21). Oxidized lipid metabolites, generated by ROS-mediated platelet 
oxidative conversion, including oxPL, lysoPC and CE, were found to be 
expressed in significantly higher amounts in platelets of CAD patients as 
compared to healthy controls. As already discussed POVPC or PGPC promote 
adhesion of monocytes to endothelium, oxLDL uptake, and formation of foam 
cells as well as apoptosis of macrophages and proliferation of smooth muscle 
cells. LysoPC are nonetheless responsible for the development of and were 
proven to independently predict the risk of CVD (79). This confirms the 
significance of inflammation and oxidative stress being as one of the primary 
factors in the pathogenesis of atherosclerosis (80). PL oxidation products 
accumulate in plasma, atheromatous plaques and are essential constituents of 
lipoproteins. Detection of oxPL in platelets suggests that platelets could be 
considered as an important source of oxPL.  
Current guidelines to CVD prevention are based on LDL-C lowering therapies 
as LDL has been proven to be an independent CVD risk factor. Statins and 
some novel agents, e. g. ezetimibe or PCSK9 inhibitors mainly lower the levels 
of LDL-C exhibiting little effect on VLDL, chylomicrons or Lp(a) etc. This study 
detected various lipid entities which are associated with CAD and are 
significantly more abundant in SAP and STEMI patients (21). The detected lipid 
metabolites may be used as novel CVD markers in the clinical practice next to 
the already established ones (TC, TAG, LDL, HDL etc.). This opens new 
possibilities in detecting high-risk CAD patients earlier and improving the 
prevention of CVD and its lethal complications. Novel lipid metabolites may also 
be used as substrate for developing new lipid-lowering therapies in 
atherosclerosis. 
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7.    Conclusion 
 
Atherosclerosis is a systemic inflammatory disease caused by 
monocyte/macrophage and leucocyte accumulation in the intima of arteries, 
leading to the formation of atheromatous plaques. This can subsequently result 
in plaque rupture and thrombotic occlusion of arteries, manifesting in various 
ischemic events (myocardial infarction, cerebral stroke, mesenteric ischemia 
etc.). Platelets contribute to the development of atherosclerosis by the means of 
aggregation, activation of endothelium, production of inflammatory cytokines, 
and thrombus formation upon plaque rupture.  
Lipids, especially oxidized lipid metabolites, also play a crucial role in the 
building of atheromatous plaques. Of crucial importance in the pathogenesis of 
atherosclerosis is the lipid-platelet interplay as oxidized lipids exhibit a 
characteristic feature to activate and enhance the functions of platelets. 
Platelets are therefore able to endocytose lipids and generate its atherogenic 
oxidation products.  
Therefore, hyperlipidaemia is one of the main cardiovascular risk factors. The 
main atherogenic lipoprotein in human bloodstream is LDL-C and is the major 
target of cholesterol-lowering therapy. On the other hand, the number of 
potential novel lipid biomarkers may grow as oxidation processes in the 
development of atherosclerosis generate a variety of oxidized lipid metabolites 
which are currently under investigation. Phospholipid oxidation can be either 
induced enzymatically or non-enzymatically. The former oxidation is initiated by 
different LOX or COX whereas the latter one by ROS. Enzymatic PL-oxidation 
creates an enormous variety of new species of oxPLs which exhibit atherogenic 
features and contribute to the pathogenesis of CAD. E.g. 12-HETE containing 
oxPLs are known for initiating or triggering pro-coagulant functions. Another 
group of PAPC-derived oxPLs (e. g. POVPC or PGPC) promotes adhesion of 
monocytes to endothelium, oxLDL uptake, and formation of foam cells as well 
as apoptosis of macrophages and proliferation of smooth muscle cells. Another 
PAPC-oxidation product PEIPC exhibits the latter functions even more potently. 
Therefore, these oxidized lipid metabolites may serve as novel laboratory 
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markers and help diagnose hyperlipidemic states earlier especially in stratifying 
high risk patients and initiating an appropriate therapeutic strategy for 
prevention of CVD.   
The findings of the current study suggest that the platelet lipid profile differs 
substantially among the healthy subjects and CAD patients. The abundance of 
detected oxidized lipid metabolites was found to be increased in acute stages of 
CAD, i.e. STEMI. The conventional concept of LDL-C being the most important 
factor in the pathogenesis of atherosclerosis might be challenged as these 
novel lipid metabolites also enhance atherosclerosis. Therefore, the detected 
metabolites may be gradually introduced as novel biomarkers to the 
conventional ones (TC, LDL-C etc.) into clinical practices and could improve the 
primary and secondary prevention of CVD. These oxidized lipid metabolites 
may also become novel therapeutic targets. Moreover, the findings of the study 
bring a better understanding of the platelet-related pathomechanisms of 
atherosclerosis. Finally, these findings contribute to the current knowledge of 
lipid metabolism and associated pathophysiology.  
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8.    Deutsche Zusammenfassung 
 
Kardiovaskuläre Erkrankungen sind eine der Hauptursachen für Mortalität in der 
industrialisierten Welt und werden bis zum Jahr 2030 für 23,6 Millionen der 
Todesfälle weltweit verantwortlich sein (1). Der akute Myokardinfarkt (AMI) und 
die damit einhergehenden Komplikationen stellen die schwerste Manifestation 
einer koronaren Herzerkrankung (KHK) und somit eine der häufigsten 
Todesursachen weltweit dar. Zur Entstehung von ischämischen Ereignissen wie 
z. B. AMI trägt die Atherosklerose maßgeblich bei. Hyperlipidämie ist ein 
entscheidender Faktor, der zur systemischen Inflammation und Pathogenese 
der Atherosklerose führt, und stellt somit einen kardiovaskulären Risikofaktor 
mit größter klinischer Bedeutung dar.   
Ziel dieser Studie war die Identifizierung des thrombozytären Lipidprofils in 
gesunden Probanden sowie Patienten mit einer KHK.  Darüber hinaus wurde 
das thrombozytäre Lipidprofil zwischen den gesunden Probanden, Patienten mit 
stabiler Angina pectoris (SAP) und ST-Hebungsinfarkt (STEMI) verglichen.  
Das Thrombozytenlipidrofil wurde bei 13 STEMI-Patienten, 10 SAP-Patienten 
und 10 gesunden Probanden mittels einer Flüssigkeitschromatographie und 
einer gekoppelten high-resolution Massenspektrometrie (UHPLC-ESI-QTOF-
MS/MS) untersucht und verglichen. 
Die Analyse der Hauptkomponenten zeigte eine signifikante Verteilung der 
Thrombozytenlipidprofile in den zwei Gruppen, welche gesunde Probanden und 
Patienten mit einer KHK darstellen (Abbildung 7). Zudem wurden signifikante 
Unterschiede zwischen den Myokardinfarktpatienten und SAP-Patienten 
beobachtet. Somit wurden die größten Mengen der unterschiedlichen Lipide 
und Lipidmetabolite in der akutesten Phase der KHK, das heißt in STEMI-
Patienten, nachgewiesen und zeigten somit einen signifikanten Unterschied im 
Vergleich mit SAP-Patienten und gesunden Probanden.  
Insgesamt konnten 664 Molekulareinheiten beobachtet werden, welche 
signifikante Mengenunterschiede zwischen den KHK-Patienten und gesunden 
Probanden zeigten. 172 Molekulareinheiten konnten manuell identifiziert 
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werden und zeigten die gleiche Tendenz bezüglich des spezifischen 
Vorkommens. Die Ergebnisse sind in einer Heatmap dargestellt und zeigen, 
dass gewisse Lipide in Patienten mit einer KHK, im Vergleich mit den gesunden 
Probanden, vermehrt (p>0,05) ausgeschüttet werden (Abbildung 8). Die 
identifizierten Lipidklassen stellten in erster Linie Triglyzeride, Phospholipide, 
Diacylglycerine, Monoacylglycerine, plasmenyl-Phosphatidylcholine, 
Sphingomyeline und Ceramide dar.  
Ein anderer wichtiger Aspekt dieser Studie war die Identifizierung des Profils 
der oxidierten Phospholipide in Thrombozyten von KHK-Patienten. Oxidierte 
Lipidenmetabolite, einschließlich oxidierter Phospholipide, 
Lysophosphatidylcholine und Ceramide, wurden in signifikant größeren Mengen 
in KHK-Patienten im Vergleich mit den gesunden Probanden sezerniert. Dies 
bestätigt die Signifikanz der entzündlichen und oxidativen Prozesse in der 
Pathogenese der Arteriosklerose (80). Phospholipidenoxidationsprodukte 
kummulieren sich in Plasma, atheromatösen Plaques und sind 
Grundbestandtteile der Lipoproteine. Somit sind die Thrombozyten 
wahrscheinlich eine der wichtigsten Quelle oxidierter Phospholipide im 
Kreislauf.  
Zusammen mit Lipoproteinen können die oxidierten Phospholipide, 
Lysophosphatidylcholine und Ceramide somit als wichtige kardiovaskuläre 
Risikofaktoren betrachtet werden. Ceramide, die reichlich in KHK-Patienten 
ausgeschüttet werden wurden vor kurzem als signifikante Prädiktoren 
kardiovaskulärer Erkrankungen bezeichnet, unabhängig von aktuellen 
Lipidmarkern (45). Lysophosphatidylcholine beschleunigen die Entwicklung 
kardiovaskulärer Erkrankungen und können somit als unabhängige Prädiktoren 
angesehen werden (79). Die oben genannten Lipidmetabolite könnten eventuell 
als neue Biomarker im klinischen Alltag angewendet werden, um die Patienten 
mit hohem kardiovaskulärem Risiko zu identifizieren. Zudem könnten diese 
Lipidmetabolite zur Erfindung neuer Medikamente zur Lipidsenkung im Blut und 
somit zur kardiovaskulären Prävention angewendet werden. Die Studie trägt 
den aktuellen Kenntnissen in der Forschung der Atherosklerose bei und 
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vertiefet das Verstehen der pathophysiologischen Mechanismen in der 
Atherosklerose.  
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